medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2015, Number 4

<< Back Next >>

Acta Med 2015; 13 (4)

Cannabinoids: current uses in clinical practice

Serra RSV, Palomares VPR, Pinto SMEAlmeida GE

Language: Spanish
References: 57
Page: 244-250
PDF size: 149.83 Kb.


ABSTRACT

Medical science has had a remarkable development in the last century. Day by day we have access to more pharmacological resources that allow us to cure and control diverse pathologies, as well as to alleviate their symptoms both securely and efficiently. Among the broad bank of pharmacological resources, there is a fuzzy yet seemingly promising group for the management of pain and associated symptoms of specific pathologies. That group is cannabinoids. Fear and taboo surround cannabinoids due to the reputation as a recreational drug of the well known Cannabis sativa or “marijuana”. In spite of it, some of its close to 70 endogenous cannabinoids or phytocannabinoids are useful for clinical practice because they selectively act in receptors of the human endocannabinoid system. In this way, they provide relief from pain and other symptoms that are refractory to conventional treatments. More research is needed to demonstrate the efficacy of this pharmacological group. However, available clinical essays shed promise on the therapeutic potential of this group.


REFERENCES

  1. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol. 2004; 141: 765-774.

  2. Lynch M. Preclinical science regarding cannabinoids as analgesics: an overview. Pain Res Manag. 2005; 10 Suppl A: 7A-14A.

  3. Di Marzo V. Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta. 1998; 1392: 153-175.

  4. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58: 389-462.

  5. Pisanti S, Malfitano AM, Grimaldi C, Santoro A, Gazzerro P, Laezza C et al. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract Res Clin Endocrinol Metab. 2009; 23: 117-131.

  6. Gálvez R, Ruiz S, Romero J. Propuesta de nueva Escalera Analgésica para el dolor neuropático. Rev Soc Esp Dolor. 2006; 6: 377-380.

  7. Gonzáles de Mejía N. Analgesia multimodal postoperatoria. Rev Soc Esp Dolor. 2005; 12 (2): 112-118.

  8. Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem. 2005; 48 (16): 5059-5087.

  9. Torres LM, Trinidad JM, Calderón E. Potencial terapéutico de los cannabinoides. Rev Soc Esp Dolor. 2012; 20 (3): 132-136.

  10. Zúñiga-Ayala M, López-Ávila A. Terapia antitumoral con el uso de cannabinoides, un descubrimiento que podría cambiar la evolución del cáncer. Gaceta Mexicana de Oncología. 2014; 13 (4): 244-251.

  11. De Vries TJ, Shaham Y, Homberg JR et al. A cannabinoid mechanism in relapse to cocaine seeking. Nature Med. 2001; 7: 1151-1154.

  12. Fattore L, Martellota MC, Cossu G et al. CB1 cannabinoid receptor agonist WIN55, 212-2 decreases intravenous cocaine self-administration in rats. Behav Brain Res. 1999; 104: 141-148.

  13. Fernández-Ruiz J, Lastres-Becker I, Cabranes A et al. Endocannabinoids and basal ganglia functionality. Protag Leukot Essent Fatty Acids. 2002; 66: 257-67.

  14. Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci. 1999; 65: 637-644.

  15. Hillard CJ. Endocannabinoids and vascular function. J Pharm Exp Ther. 2000; 294: 27-32.

  16. Guindon J, Hohmann AG, Beaulieu P. Pharmacology of the cannabinoid system. In: Beaulieu P, Lussier D, Porreca F, Dickenson AH, eds. Pharmacology of pain. Seattle: IASP Press; 2010: pp. 111-138.

  17. Redmond WJ, Goffaux P, Potvin S et al. Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin. 2008; 24: 1017-1024.

  18. Grotenhermen F. Los cannabinoides y el sistema endocannabinoide. Cannabinoids. 2006; 1 (1): 10-14.

  19. Guindon J, Hohman AG. The endocannabinoid system and pain. CNS Meurol Disord Drug Targets. 2009; 8: 403-421.

  20. Christie MJ, Mallet C. Endocannabinoids can open the pain gate. Sci Signal. 2009; 2 (88): pe57.

  21. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005; 68 (5): 1484-1495.

  22. Rukwied R, Watkinson A, McGlone F et al. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain. 2003; 102: 283-288.

  23. Naef M, Curatolo M, Petersen-Felix S et al. The analgesic effect of oral delta 9 tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003; 105: 79-88.

  24. Jain AK, Ryan JR, McMahon FG et al. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 1981; 21 (8-9 Suppl): 320S-326S.

  25. Holdcroft A, Maze M, Doré C et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006; 104: 1040-1046.

  26. Buggy DJ, Toogood L, Maric S et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain. 2003; 106: 169-172.

  27. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth. 2006; 53: 769-775.

  28. Martín-Sánchez E, Furukawa TA, Taylor J et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009; 10: 1353-1368.

  29. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011; 72: 735-744.

  30. Wade DT, Robson P, House H et al. A preliminary controlled study to determine whether whole plan cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003; 17: 21-29.

  31. Berman JS, Symonds C, Birch R. Efficacy of two cannabis-based medicinal extracts for relief of central neurophatic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain. 2004; 112: 299-306.

  32. Notcutt W, Price M, Miller R et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 “N of 1” studies. Anaesthesia. 2004; 59: 440-452.

  33. Numikko TJ, Serpell MG, Hoggart B et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomized, double blind, placebo controlled clinical trial. Pain. 2007; 133: 210-220.

  34. Abrams DI, Jay CA, Shade SB et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007; 68: 515-521.

  35. Ellis RJ, Toperoff W, Vaida F et al. Smoked medicinal cannabis for neurophatic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009; 34: 672-680.

  36. Richardson D, Pearson RG, Kurian N et al. Characterisation of the cannabinoid receptor system in sinovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008; 10: R43.

  37. Burstein S, Levin E, Varanelli C. Prostaglandins and cannabis. Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochem Pharmacol. 1973; 22 (22): 2905-2910.

  38. Schaefer CF, Brackett DJ, Gunn CG, Dubowski KM. Decreased platelet aggregation following marihuana smoking in man. J Okla State Med Assoc. 1979; 72 (12): 435-436.

  39. Fimiani C, Liberty T, Aquirre AJ, Amin I, Ali N, Stefano GB. Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins Other Lipid Mediat. 1999; 57 (1): 23-34.

  40. Evans FJ. Cannabinoids: the separation of central from peripheral effects on a structural basis. Planta Med. 1991; 57 (7): S60-S77.

  41. Stott CG, Guy GW, Wright S et al. The effects of cannabis extracts Tetranabinex and Nabidiolex on human cyclo-oxygenase (COX) activity. International Cannabinoid Research Society; 2005.

  42. Fish M, Burton A. Prevention and treatment of opioid side effects. Cancer Pain Management. Chicago: McGraw Hill; 2007: pp. 39-46.

  43. Johnson JR, Burnell-Nugent M, Lossignol D et al. Multicenter, double blind, randomized, placebo controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010; 39: 167-179.

  44. Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol. 2011; 163: 1447-1463.

  45. Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs. 2003; 12 (1): 39-49.

  46. Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs. 2003; 17 (3): 179-202.

  47. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry. 2001; 178: 107-115.

  48. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 2003; 11: 137-143.

  49. Barann M, Molderings G, Brüss M, Bönisch H, Urban BW, Göthert M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol. 2002; 137: 589-596.

  50. Hama A, Sagen J. Antinociceptive effect of cannabinoid agonist. WIN 55.212-2 in rats with a spinal cord injury. Exp Neurol. 2007; 204: 454-457.

  51. García-Ovejero D, Arevalo-Martín A, Petrosino S et al. The endoccanabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis. 2009; 33 (1): 57-71.

  52. Hagenbach U, Luz S, Ghafoor N et al. The treatment of spasticity with delta 9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord. 2007; 45: 551-552.

  53. Pertwee RG. Cannabinoids and multiple sclerosis. Mol Neurobiol. 2007; 36: 45-59.

  54. Wade DT, Makela PM, House H et al. Long-term use of a cannabinoid-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006; 12: 639-645.

  55. Sánchez-Lázaro IJ, Almenar-Bonet L, Sancho-Tello MJ, Martínez-Dolz L. Taquicardia ventricular por cannabis en trasplantado cardiaco. Rev Esp Cardiol. 2009; 62: 459-461.

  56. Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol. 2007; 118: 141-144.

  57. Hine B, Friedman E, Torrelio M et al. Morphine dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science. 1975; 187: 443-445.




2020     |     www.medigraphic.com